4-month Rifapentine-Moxifloxacin-Isoniazid-Pyrazinamide (RPT-M-H-Z) Regimen
Treatment for Hiv Aids Drug Susceptible Tuberculosis
Typical Dosage: Weight-based daily dosing for Rifapentine, Moxifloxacin, Isoniazid, Pyrazinamide
Effectiveness
88%
Safety Score
55%
Clinical Trials
50
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
Weight-based daily dosing for Rifapentine, Moxifloxacin, Isoniazid, Pyrazinamide
Time to Effect
1-2 weeks for clinical improvement, 2-4 weeks for sputum conversion
Treatment Duration
4 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
1(Treat 1 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,160
Monitoring:$1,500
Side Effect Mgmt:$400
Total Annual:$3,060
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$7,500/QALY
QALYs Gained
12
Outcome-Based Costs
Cost per Responder
$3,477
Cost per Remission
$3,687
Comparison vs Standard 6-month HRZE/HR Regimen
Cost Difference
$-270/year
Less expensive
QALY Difference
+0.02 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
4-month Rifapentine-Moxifloxacin-Isoniazid-Pyrazinamide (RPT-M-H-Z) Regimen Outcomes
for Hiv Aids Drug Susceptible Tuberculosis
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+88%
Remission Rate
+83%
Common Side Effects
Gastrointestinal upset (nausea, vomiting, diarrhea)
+20%
Hepatotoxicity (elevated LFTs, hepatitis)
+8%
Peripheral neuropathy
+5%
Orange/red discoloration of urine/tears/sweat
+99%
Rash
+7%
QT prolongation
+1%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov